Legnago

• Study comparing single versus dual antiplatelet therapy in elderly patients or patients at risk of bleeding undergoing balloon surgery. Recruiting
  2024-519706-13-00 6 2026-01-26 Patients with Stable or Unstable coronary syndromes who have undergone
• A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-li … Recruiting
  2024-518224-74-01 4 2025-02-07 metastatic non-small-cell lung cancer
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• Efecto de la inmunoterapia en pacientes con cáncer de pulmón de células no pequeñas oligometastásico (número limitado de metástasis) después … Recruiting
  2023-508741-40-00 10 2025-01-14 Non-small cell lung cancer
• MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The M … Recruiting
  2024-516841-38-00 4 2025-01-09 recurrent ovarian cancer wild type for germline and somatic BRCA 1 and
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli … Recruiting
  2024-512671-12-00 10 2021-03-05 Unresectable head and neck squamous cell carcinoma, metastatic head an
• A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer Ended recruitment
  2024-514080-25-00 5 2023-04-21 Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
• PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended recruitment
  2023-505057-40-00 4 2022-12-02 Lung Cancer, Non-Small Cell
• Adjuvant therapy in stage IV colorectal cancer patients NED Ended recruitment
  2024-518217-26-00 4 2021-10-20 Stage IV colorectal cancer patients with no evidence of disease (NED)
• MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar … Ended recruitment
  2024-516632-99-00 4 2021-03-17 Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk … Ended recruitment
  2023-505223-31-00 4 2019-06-14 Localized ER+ breast cancer
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted
  2024-515152-20-00 4 2023-03-02 Stage III and high-risk stage II resected colon cancer patients.
• European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended
  2022-500385-99-00 5 2021-06-03 SARS-CoV II infection (Coronavirus disease)
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung Cancer Ended
  2022-500990-16-00 4 2018-12-19 Stage IV non-small cell lung cancer

Showing 1–22 of 22 trials